Aether Industries LtdQ1 FY27
Aether Industries Ltd Q1 FY27 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Price: ₹1,646P/E: 90.0Market Cap: ₹21.6K CrSector: Chemicals & Petrochemicals
Management growth scorecard
Revenue
Category 2
Margin
Category 3
Fundraise
N/A
Order
Yes
Capex
Yes
2 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 2- →CEM (Contract Exclusive Manufacturing) and CRAMS (Contract Research and Manufacturing Services) are expected to contribute over 70% of revenue in the next couple of years, indicating strong growth in these high-margin segments.
- →Site 3++ block ramp-up and Site 5 commissioning are on schedule, which will increase production capacity and sales in upcoming quarters.
- →New customer onboarding and more than nine customer audits cleared in Q1 FY27 signal a strong and growing order pipeline.
- →Organic growth in the oil and gas segment, which already accounts for around 20% of revenue and expected to increase further.
- →Semiconductor and material science segments have high growth potential with multiyear R&D programs underway, including new product commercialization starting Q2 FY27.
- →Strategic partnership with Dow targets the billion-dollar silicone market in India, aiming for long-term technology commercialization and growth.
- →Progressive working capital management and capex (~INR 3,000-3,500 million for FY27) support expansion and revenue growth.
Margin guidance
Category 3- →Aether expects continued strong growth with expanding Contract Exclusive Manufacturing (CEM) and CRAMS models, aiming for these two segments to contribute over 70% of revenue in the next couple of years.
- →EBITDA margins for CEM currently range between 28%-30%, with rising margins as the mix shifts toward higher-margin CEM contracts.
- →The company is scaling new capacities (Site 3++ and Site 5), which are expected to improve working capital efficiency and revenue realization.
- →Oil & Gas segment is already about 20% of business and is expected to grow further in coming years.
- →Semiconductor and material science segments are in multiyear R&D/commercialization phases, with commercial production targeted around late 2026/early 2027, offering future margin expansion.
- →The partnership with Dow Chemical is a landmark opportunity that may open up significant future revenue streams in advanced silicones.
- →Q1 FY27 PAT grew 33% YoY, signaling strong profitability momentum.
3 more insights locked — sign up free to unlock
Fundraise plans
- →There is no explicit mention of any current or planned fundraising through debt or equity in the transcript.
- →The company discussed ongoing capex plans with expected expenditure between INR 3,000 million to INR 3,500 million in FY27, primarily for Site 5 and a new R&D site.
- →The management emphasized working capital discipline and sustained reduction in working capital intensity but did not mention any new financing.
- →No direct comments on fundraising activities (debt or equity) were provided during the Q&A or closing remarks.
- →When asked about investment size in R&D (specifically related to Dow collaboration), the company declined to disclose details but confirmed significant investment. However, this is related strictly to operational investments, not fundraising.
Order book
Yes- →The company does not disclose detailed order book or product count for competitive reasons at this stage. (Page 14)
- →Commercial sales for new LSM products at Site 5 started in Q1 FY27, with revenue contribution expected from Q2 FY27. (Page 14)
- →Order buildup is in progress for new LSM products across pharmaceutical, agrochemical, and material science sectors. (Page 14)
- →The CEM and CRAMS pipelines are described as the deepest ever, with strong order visibility and rising urgency from Western customers in FY27. (Page 7)
- →No specific numbers or values for pending orders were disclosed publicly. (Page 14, 7)
Capex plans
Yes- →Total capex for Q1 FY27 was INR 943 million.
- →Capex expected for FY27 is between INR 3,000 million to INR 3,500 million.
- →FY27 capex primarily allocated to Site 5 and the new R&D site, which is progressing well.
- →Expansion includes Site 3++ ramp-up and capacity scaling at Site 5.
- →Strategic investments include building manufacturing capacity near Surat at Panoli (Magnum Site 5).
- →Focus on concurrent expansions in R&D, pilot plants, and manufacturing assets.
- →Investment aligned with technology development, including multi-year R&D programs (e.g., Dow partnership for silicone technology).
- →Emphasis on capital efficiency and working capital discipline alongside capex.
How does Aether Industries Ltd rank vs peers in Chemicals & Petrochemicals?
Pro feature1Aether Industries Ltd
Rev 2Mar 3
See full Chemicals & Petrochemicals sector rankings
How does Aether Industries Ltd rank in Chemicals & Petrochemicals?
Compare Aether Industries Ltd against every Chemicals & Petrochemicals company (Q1 FY27) on revenue, margins and earnings-call signals.